## Enhanced Meningococcal Disease Surveillance GENERIC MMG Data Collection Guidance Worksheet RIBD\_V1\_0\_MMG\_F\_20191003

NNDSS Case ID: OBR-3	State ID: 77993	Laboratory ID: INV978			
DOB PID-7 / / OR Age: yea	irs old 77998-3	Case Status: 77990-0 Confirmed Probable			
Event date: / /		Source: 66746-9 Blood CSF Other (specify)			
Lab confirmation method: INV290         Culture       PCR         Latex       Other         Unknown		Test used to serogroup:       LAB652         Slide agglutination (SASG)       PCR       WGS       Other			
Serogroup:       INV705       A       B       C       E         X       Y       Not groupable       Other (specify)         Outcome:       77978-5       Survived       Died		Symptoms: 56831-1       Yes       No INV919       Unknown         Headache       25064002			
Outbreak/Cl 77980-1 elated: Yes No	] Unknown	Photophobia 409668 02			
Homeless: 32911000 Yes No	] Unknown	Vomiting 422400008			
College Student:       Yes       No       Unknown         224311000       If yes, please complete the following questions         Year in School:       Freshman       Sophomore       Junior		Sore throat			
Senior Graduate Student Other	_	Other Unknown Other (specify) OTH UNCLEAR Unknown Unknown Unknown			
		HIV Status: 55277-8 Yes No Unknown			
MSM (men who have sex with men) – Complete these variables for any male cases 16 years of age and older.          During the past 12 months, have you had sex with only males, only females, or with both males and females?         Males only       Females only         Both males and females       Not sexually active         Unknown       Refused					
MSM not otherwise specified: Yes No Unknown					
Taking complement inhibitor:       Yes, eculizumab/Soliris       Yes, ravulizumab/Ultomiris       No       Unknown         If yes, please complete the complement inhibitor case information table below					
COMPLEMENT INHIBITOR CASE INFORMATION*					
Indication for complement inhibitor treatment:       Paroxysmal nocturnal hemoglobinuria (PHN)       Unknown         Generalized myasthenia gravis (gMG)       Atypical hemolytic uremic syndrome (aHUS)       Other					
Date complement inhibitor treatment started: / /  Unknown					
Date complement inhibitor treatment ended: / / On-going Unknown					
Hospitalized?       Yes ( ) days       No       Unknown       77974-4       Sequelae:       Yes:					
Was the patient taking antibiotics at the time of disease onset? Yes No Unknown If yes:					
Antibiotic:	_ Date antibioti	ic started: / / Daily dose:			

\*These variables are part of a supplemental data collection activity that is NOT part of NNDSS meningococcal disease surveillance. This is included as a convenience for jurisdictions who choose to participate in this supplemental data collection. Jan 2019 Page

VACCINATION INFORMATION						
Did the patient receive qu Did the patient receive se	Inknown Jnknown Jnknown Jnknown					
Date 30952-6	Vaccine					
	<b>Type</b> 30956-7	Name VAC155	Lot Number 30959-1			
	D MenACWY					
	D MenB					
/ /	D Other:					
D Unknown	D Unknown					
	D MenACWY					
/ / D Unknown	D MenB					
	D Other:					
	D Unknown					
	D MenACWY					
/ / D Unknown	D MenB					
	D Other:					
	D Unknown					
/ / D Unknown	D MenACWY					
	D MenB					
	D Other:					
	D Unknown					
	MenACWY					
1 1	🗅 MenB					
	D Other:					
D Unknown	D Unknown					